Gotham Asset Management LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Gotham Asset Management boosted its stake in Regeneron by 211.9% in Q3 to 84,230 shares, holding about $47.36 million (0.08% of the company) after buying an additional 57,225 shares.
• Analysts are broadly positive with an average rating of "Moderate Buy" and an average target of $802.27, while some firms set higher targets (JPMorgan $950, Barclays $923 and HSBC issuing a strong-buy).
• Insiders have sold 5,274 shares (~$4.14 million) in the past 90 days, even as Regeneron raised its quarterly dividend to $0.94 (annualized $3.76, ~0.5% yield).

Gotham Asset Management LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 211.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 84,230 shares of the biopharmaceutical company's stock after purchasing an additional 57,225 shares during the quarter. Gotham Asset Management LLC owned 0.08% of Regeneron Pharmaceuticals worth $47,360,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of REGN. Salomon & Ludwin LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $31,000. Caitlin John LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $34,000. Traub Capital Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $38,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 87.5% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 35 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on REGN shares. HSBC raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Monday, November 24th. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a "buy" rating on the stock in a report on Monday, February 2nd. JPMorgan Chase & Co. increased their price target on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an "overweight" rating in a research report on Monday, February 2nd. Barclays assumed coverage on Regeneron Pharmaceuticals in a research note on Friday, March 6th. They set an "overweight" rating and a $923.00 price objective for the company. Finally, Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an "equal weight" rating in a research note on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $802.27.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of the firm's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 5,274 shares of company stock worth $4,142,738 in the last ninety days. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Trading Down 0.1%

Shares of REGN stock opened at $745.77 on Monday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a market cap of $78.84 billion, a price-to-earnings ratio of 17.94, a PEG ratio of 2.00 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The stock has a 50 day simple moving average of $769.73 and a 200-day simple moving average of $695.68.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter last year, the company earned $12.07 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.